Currently, Johan Erik Häggblad holds the position of Chief Scientific Officer at Calliditas Therapeutics AB and Deputy Director at Nefecon AB (a subsidiary of Calliditas Therapeutics AB).

He is also on the board of Pharmalink Oncology AS and Deputy Director at Nefecon AB, Deputy Director at Busulipo AB and Deputy Director at Pharmalink Nordic AB.

In his past career he was Principal at Karo Pharma AB, Principal at Pharmacia Corp. and Principal at Newron Sweden AB.

Dr. Häggblad received a doctorate and an undergraduate degree from the University of Stockholm.